News

Tikcro has reported that the US Department of Health and Human Services (HHS) has granted orphan drug status to BioCancell’s BC-819 drug. It is currently in phase I/IIa

Abbott has received approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease (CAD). Reportedly, Xience V is

CytRx has reported positive results of the study evaluating arimoclomol. The data demonstrated that arimoclomol exhibited both significant neuroprotective and neuroregenerative effects in brain cells of animals induced

Covidien has launched Leak Compensation software option for the Puritan Bennett 840 ventilator. The company claims that the new feature will provide a ventilation solution in high-leak environments,

Micrus (MEND) and Flexible Stenting Solutions have selaed an agreement to jointly develop a flow diversion technology for neurovascular indications, using their technology, development capabilities and intellectual property.

Perrigo has acquired 85% stake of Vedants Drugs and Fine Chemicals. The company now plans to move its active pharmaceutical ingredients (API) manufacturing units from Israel and Germany

Roche has sealed a deal with Pontifax Management to build a R&D pipeline in Israel. Under the agreement, Pontifax will help Roche to identify and invest in Israeli

Stemedica Cell Technologies has requested a pre-Investigational New Drug (IND) meeting with the FDA. The purpose is to discuss a proposed IND to use Stemedica’s proprietary line of

Astellas has announced that the groundbreaking ceremony for Fermentation Technology Research Building in the Toyama Plant of its subsidiary, Astellas Toyama, will be held on August 24, 2009.